Novartis adds to China commitment opening new R&D campus in Shanghai

Today Swiss pharma giant Novartis (NOVN: VX) and the Zhangjiang Hi-Tech Park Administrative Committee co-hosted an Innovation Forum at the new Novartis R&D campus. The forum focused on how industry, academia and government can collaborate to help Shanghai continue to develop as a global center for scientific and technological innovation.

Speaking at the Innovation Forum, Novartis chief executive Joseph Jimenez said: “China is a growing force in the next wave of healthcare innovation.Today we are celebrating our sharedcommitment to innovation and inaugurating our new R&D campus which embodies our confidence and commitment to China for the long term.”

Novartis’ Shanghai Campus is one of the company’s three major R&D centers globally, along with those in Basel, Switzerland, and Cambridge, MA, USA. It is home to more than 1,000 associates and includes two world-class research laboratory buildings for scientists working for the Novartis Institutes for BioMedical Research (NIBR). It also has four office buildings for the company’s innovative medicines, eye care (Alcon), and generics (Sandoz) divisions.